Funding

Dioseve

Japan · Biotech · Healthtech

Develops iPS cell-derived co-culture technology to improve oocyte maturation and reduce IVF treatment burden

Visit dioseve.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Series A+$7MArchetype Ventures — Role not disclosedD4V — Role not disclosedDG Daiwa Ventures — Role not disclosedMirai Door (Asuka Innovation Fund) — Role not disclosedPangaea Ventures — Role not disclosedShionogi & Co — Role not disclosed

Investors

Archetype VenturesSeries A+D4VSeries A+DG Daiwa VenturesSeries A+Mirai Door (Asuka Innovation Fund)Series A+Pangaea VenturesSeries A+Shionogi & CoSeries A+

Coverage

Jun 16, 2026Dioseve · Series A+

Similar companies

Guoke Brain-ComputerBeijing startup developing non-invasive wearable brain-computer interfaces that combine brain-signal detection, decoding and neural modulation.Undisclosed · Seed
Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
Sourcesdioseve.com ↗